相似文献
1
Beggars banquet: Metabolism in the tumor immune microenvironment and cancer therapy.
Cell Metab. 2023 Jul 11;35(7):1101-1113. doi: 10.1016/j.cmet.2023.06.003. Epub 2023 Jun 29.
2
Targeting SLC1A5 and SLC3A2/SLC7A5 as a Potential Strategy to Strengthen Anti-Tumor Immunity in the Tumor Microenvironment.
Front Immunol. 2021 Apr 19;12:624324. doi: 10.3389/fimmu.2021.624324. eCollection 2021.
3
Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy.
Cell Metab. 2017 Jul 5;26(1):94-109. doi: 10.1016/j.cmet.2017.06.016.
4
The roles of epigallocatechin gallate in the tumor microenvironment, metabolic reprogramming, and immunotherapy.
Front Immunol. 2024 Jan 29;15:1331641. doi: 10.3389/fimmu.2024.1331641. eCollection 2024.
5
The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy.
Elife. 2020 May 5;9:e55185. doi: 10.7554/eLife.55185.
6
Dysfunctional T cell metabolism in the tumor microenvironment.
Cytokine Growth Factor Rev. 2017 Jun;35:7-14. doi: 10.1016/j.cytogfr.2017.04.003. Epub 2017 Apr 23.
7
Targeting Tumor Metabolism: A New Challenge to Improve Immunotherapy.
Front Immunol. 2018 Feb 23;9:353. doi: 10.3389/fimmu.2018.00353. eCollection 2018.
8
Metabolism of Immune Cells in the Tumor Microenvironment.
Adv Exp Med Biol. 2021;1311:173-185. doi: 10.1007/978-3-030-65768-0_13.
9
Harnessing Metabolic Reprogramming to Improve Cancer Immunotherapy.
Int J Mol Sci. 2021 Sep 24;22(19):10268. doi: 10.3390/ijms221910268.
10
Tumor microenvironment metabolites directing T cell differentiation and function.
Trends Immunol. 2022 Feb;43(2):132-147. doi: 10.1016/j.it.2021.12.004. Epub 2021 Dec 29.
引用本文的文献
1
T cells require mitochondria to proliferate, function and generate memory.
Nat Immunol. 2025 Jul 22. doi: 10.1038/s41590-025-02226-3.
2
Deciphering cancer therapy resistance via patient-level single-cell transcriptomics with CellResDB.
Commun Biol. 2025 Jul 15;8(1):1049. doi: 10.1038/s42003-025-08457-2.
3
Enhancing CAR-T Cell Metabolic Fitness and Memory Phenotype for Improved Efficacy against Hepatocellular Carcinoma.
Int J Biol Sci. 2025 Jun 20;21(9):4231-4251. doi: 10.7150/ijbs.110406. eCollection 2025.
4
Targeting Metabolic Reprogramming in Bladder Cancer Immunotherapy: A Precision Medicine Approach.
Biomedicines. 2025 May 9;13(5):1145. doi: 10.3390/biomedicines13051145.
5
Research trends on lactate in cancer: a bibliometric analysis and comprehensive review (2015-2024).
Front Immunol. 2025 May 9;16:1587867. doi: 10.3389/fimmu.2025.1587867. eCollection 2025.
6
Integrative single-cell RNA sequencing and bulk RNA sequencing reveals the characteristics of glutathione metabolism and protective role of GSTA4 gene in pancreatic cancer.
Front Immunol. 2025 May 1;16:1571431. doi: 10.3389/fimmu.2025.1571431. eCollection 2025.
7
Metabolic characterization and radiomics-based composite model for breast cancer immune microenvironment types using F-FDG PET/CT.
Eur J Nucl Med Mol Imaging. 2025 May 6. doi: 10.1007/s00259-025-07306-y.
8
Immunomodulatory behavior of CircRNAs in tumor microenvironment.
Oncol Res. 2025 Apr 18;33(5):1105-1119. doi: 10.32604/or.2024.054623. eCollection 2025.
9
The application of organoids in investigating immune evasion in the microenvironment of gastric cancer and screening novel drug candidates.
Mol Cancer. 2025 Apr 26;24(1):125. doi: 10.1186/s12943-025-02328-4.
10
Lipid metabolism involved in progression and drug resistance of breast cancer.
Genes Dis. 2024 Jul 15;12(4):101376. doi: 10.1016/j.gendis.2024.101376. eCollection 2025 Jul.
本文引用的文献
1
Extracellular acidosis restricts one-carbon metabolism and preserves T cell stemness.
Nat Metab. 2023 Feb;5(2):314-330. doi: 10.1038/s42255-022-00730-6. Epub 2023 Jan 30.
2
Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy.
Cancer Cell. 2023 Feb 13;41(2):304-322.e7. doi: 10.1016/j.ccell.2022.12.008. Epub 2023 Jan 12.
3
Immunoediting instructs tumor metabolic reprogramming to support immune evasion.
Cell Metab. 2023 Jan 3;35(1):118-133.e7. doi: 10.1016/j.cmet.2022.12.003.
4
Myeloid-derived itaconate suppresses cytotoxic CD8 T cells and promotes tumour growth.
Nat Metab. 2022 Dec;4(12):1660-1673. doi: 10.1038/s42255-022-00676-9. Epub 2022 Nov 14.
5
Oncometabolite d-2HG alters T cell metabolism to impair CD8 T cell function.
Science. 2022 Sep 30;377(6614):1519-1529. doi: 10.1126/science.abj5104. Epub 2022 Sep 29.
6
Lactate increases stemness of CD8 + T cells to augment anti-tumor immunity.
Nat Commun. 2022 Sep 6;13(1):4981. doi: 10.1038/s41467-022-32521-8.
7
Succinate uptake by T cells suppresses their effector function via inhibition of mitochondrial glucose oxidation.
Cell Rep. 2022 Aug 16;40(7):111193. doi: 10.1016/j.celrep.2022.111193.
8
Tumor cells dictate anti-tumor immune responses by altering pyruvate utilization and succinate signaling in CD8 T cells.
Cell Metab. 2022 Aug 2;34(8):1137-1150.e6. doi: 10.1016/j.cmet.2022.06.008. Epub 2022 Jul 11.
9
cBAF complex components and MYC cooperate early in CD8 T cell fate.
Nature. 2022 Jul;607(7917):135-141. doi: 10.1038/s41586-022-04849-0. Epub 2022 Jun 22.
10
Increase in serum choline levels predicts for improved progression-free survival (PFS) in patients with advanced cancers receiving pembrolizumab.
J Immunother Cancer. 2022 Jun;10(6). doi: 10.1136/jitc-2021-004378.
Zotero 插件